December 11, 2021 07:00 AM EST

ASH: Servier unveils full dataset for Tibsovo in specific AML mutations, and the FDA appears a stone's throw away

Max Gelman

Senior Editor

Back in August, Servier revealed that a Phase III study for Tibsovo saw results so efficacious that investigators recommended stopping the trial early. Now …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ASH: Servier unveils full dataset for Tibsovo in specific AML mutations, and the FDA appears a stone's throw away

Max Gelman

Senior Editor

Sign up to read this article for free.

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

BeiGene will rebrand to BeOne Medicines, dropping name's link to China roots

As bluebird projects more commercial demand, the biotech continues to seek cash

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

ASH: Servi­er un­veils full dataset for Tib­so­vo in spe­cif­ic AML mu­ta­tions, and the FDA ap­pears a stone's throw away

Max Gelman

Senior Editor

Sign up to read this article for free.

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

ASH: Servier unveils full dataset for Tibsovo in specific AML mutations, and the FDA appears a stone's throw away

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

BeiGene will rebrand to BeOne Medicines, dropping name's link to China roots

As bluebird projects more commercial demand, the biotech continues to seek cash

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?